Investigational Drug Information for Centanafadine
✉ Email this page to a colleague
What is the development status for investigational drug Centanafadine?
Centanafadine is an investigational drug.
There have been 15 clinical trials for Centanafadine.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 16th 2019.
The most common disease conditions in clinical trials are Attention Deficit Disorder with Hyperactivity, Hyperkinesis, and Disease. The leading clinical trial sponsors are Otsuka Pharmaceutical Development & Commercialization, Inc., Neurovance, Inc., and [disabled in preview].
There are eleven US patents protecting this investigational drug and eighty-four international patents.
Summary for Centanafadine
| US Patents | 11 |
| International Patents | 84 |
| US Patent Applications | 54 |
| WIPO Patent Applications | 17 |
| Japanese Patent Applications | 6 |
| Clinical Trial Progress | Phase 3 (2019-01-16) |
| Vendors | 29 |
Recent Clinical Trials for Centanafadine
| Title | Sponsor | Phase |
|---|---|---|
| Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 |
| A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD) | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 |
| A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder. | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 |
Clinical Trial Summary for Centanafadine
Top disease conditions for Centanafadine
Top clinical trial sponsors for Centanafadine
US Patents for Centanafadine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Centanafadine | ⤷ Sign Up | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. (Rockville, MD) | ⤷ Sign Up |
| Centanafadine | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Centanafadine | ⤷ Sign Up | Crystalline compounds | OTSUKA AMERICA PHARMACEUTICAL, INC. (Rockville, MD) | ⤷ Sign Up |
| Centanafadine | ⤷ Sign Up | Crystalline compounds | OTSUKA AMERICA PHARMACEUTICAL, INC. (Rockville, MD) | ⤷ Sign Up |
| Centanafadine | ⤷ Sign Up | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | Dov Pharmaceutical (N/A) | ⤷ Sign Up |
| Centanafadine | ⤷ Sign Up | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | Neurovance, Inc. (Cambridge, MA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Centanafadine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Centanafadine | Australia | AU2006275870 | 2025-07-27 | ⤷ Sign Up |
| Centanafadine | Brazil | BRPI0613943 | 2025-07-27 | ⤷ Sign Up |
| Centanafadine | Canada | CA2659215 | 2025-07-27 | ⤷ Sign Up |
| Centanafadine | China | CN101272781 | 2025-07-27 | ⤷ Sign Up |
| Centanafadine | China | CN104059013 | 2025-07-27 | ⤷ Sign Up |
| Centanafadine | Denmark | DK2719384 | 2025-07-27 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
